Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
The change of name has been carried on pursuant to the Scheme of Amalgamation
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited
Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval
Subscribe To Our Newsletter & Stay Updated
